


ATTACHMENT 1

Claims on Appeal

¹
~~3~~. A N¹-monosubstituted polyamine analogue or derivative represented by the formula



wherein R is selected from a D or L amino acid; D or L ornithine, an alicyclic, a single or multi-ring aromatic; aliphatic-substituted single or multi-ring aromatic; and a substituted or unsubstituted, single or multi-ring heterocyclic and

Insert 10/13/2005

wherein said analogue or derivative does not have a formula represented by ID 1022, 1043, or 1202.

²
~~35~~. An analogue or derivative according to claim ¹~~3~~ wherein R is a D or L amino acid or D or L ornithine.

Pg 2 Oct 2005
³
~~32~~ ³⁴. A composition comprising a polyamine analogue or derivative according to claim ~~32~~ or ~~33~~ and a pharmaceutically acceptable excipient.

⁴
~~35~~. A composition comprising a polyamine analogue or derivative according to claim 3, a pharmaceutically acceptable excipient, and an inhibitor of polyamine synthesis.

⁵
~~36~~. A composition according to claim ⁴~~35~~ wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

⁶
~~37~~. A method for treating a disease or a condition in a subject associated with undesired cell proliferation and/or which is treatable by inhibition of polyamine transport, comprising administering to said subject a polyamine analogue or derivative according to claim ¹~~3~~.

⁷
~~38~~. A method according to claim ⁶~~37~~ wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cells of the vascular neointima, tumor cells or with undesired angiogenesis.

⁸
~~39~~. A method according to claim ⁶~~37~~ wherein said disease or condition is cancer or post-angioplasty injury.

⁹
~~40~~. A method according to claim ⁶~~37~~ further comprising administration of an inhibitor of polyamine synthesis.

¹
~~41~~. A method according to claim ⁹~~40~~ wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

¹
~~42~~. A composition according to claim ⁴~~38~~ or ⁵~~36~~ in solid form

²
~~43~~. A composition according to claim ⁴~~38~~ or ⁵~~36~~ in liquid form.

¹³
~~44~~. A method according to any one of claims ⁶~~37~~-¹¹~~41~~ wherein said administering is performed orally, parenterally, topically, transdermally, intravaginally, intranasally, intrabronchially, intracranially, intraocularly, intraaurally, or rectally, or by injection.

¹⁴
~~45~~. A method according to claim ¹³~~44~~ wherein said administering by injection is intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.

47. A composition comprising a ~~polyamine~~ analogue or derivative according to claim 46 and a pharmaceutically acceptable excipient.

48. A method for treating ~~a disease or a condition~~ in a subject comprising administering to said subject a ~~polyamine~~ analogue or derivative according to claim 46.

add
C 4 7

¹⁵
~~49~~. (New) The analogue or derivative of claim ¹~~3~~, wherein said substituted or unsubstituted heterocyclic is a pyrrolidine or a substituted pyrrolidine.

¹⁶
~~50~~. (New) The analogue or derivative of claim ¹⁵~~49~~, wherein said substituted pyrrolidine is an N-substituted pyrrolidine.

¹⁷
~~51~~. (New) The analogue or derivative of claim ¹⁶~~50~~ represented by the formula ID

1158.

¹⁸
~~52~~. (New) The analogue or derivative of claim ¹~~3~~ represented by the formula ID 1224.

¹⁴
~~53~~. (New) A method according to claim ⁶~~37~~ wherein said condition is associated with

cancer.
